DENTSPLY SIRONA Inc. (XRAY) Upgraded at TheStreet
Other equities analysts have also recently issued research reports about the stock. HC Wainwright restated a buy rating and set a $68.00 target price on shares of DENTSPLY SIRONA in a research note on Tuesday, October 3rd. Jefferies Group LLC lowered their target price on shares of DENTSPLY SIRONA from $72.00 to $66.00 and set a buy rating on the stock in a research note on Wednesday, August 23rd. Stifel Nicolaus restated a buy rating and set a $66.00 target price (down previously from $70.00) on shares of DENTSPLY SIRONA in a research note on Thursday, August 10th. Zacks Investment Research upgraded shares of DENTSPLY SIRONA from a hold rating to a buy rating and set a $72.00 target price on the stock in a research note on Thursday, July 13th. Finally, Robert W. Baird set a $63.00 target price on shares of DENTSPLY SIRONA and gave the company a buy rating in a research note on Thursday, October 19th. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and seven have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus target price of $67.00.
DENTSPLY SIRONA (NASDAQ:XRAY) traded down $0.93 on Friday, reaching $63.87. 2,834,848 shares of the company’s stock traded hands, compared to its average volume of 2,280,000. The company has a quick ratio of 1.59, a current ratio of 2.32 and a debt-to-equity ratio of 0.21. The company has a market cap of $14,700.00, a PE ratio of 25.82, a P/E/G ratio of 2.66 and a beta of 1.27. DENTSPLY SIRONA has a 1-year low of $52.53 and a 1-year high of $67.95.
DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Friday, November 3rd. The medical instruments supplier reported $0.70 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.66 by $0.04. The business had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $978.99 million. DENTSPLY SIRONA had a negative net margin of 20.33% and a positive return on equity of 7.56%. The business’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.66 EPS. research analysts forecast that DENTSPLY SIRONA will post 2.67 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “DENTSPLY SIRONA Inc. (XRAY) Upgraded at TheStreet” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.watchlistnews.com/dentsply-sirona-inc-xray-upgraded-at-thestreet/1685964.html.
Large investors have recently modified their holdings of the company. Veritas Asset Management LLP lifted its stake in shares of DENTSPLY SIRONA by 2.6% in the 2nd quarter. Veritas Asset Management LLP now owns 6,201,155 shares of the medical instruments supplier’s stock worth $402,083,000 after purchasing an additional 157,616 shares during the period. Royce & Associates LP lifted its stake in shares of DENTSPLY SIRONA by 23.4% in the 2nd quarter. Royce & Associates LP now owns 126,650 shares of the medical instruments supplier’s stock worth $8,212,000 after purchasing an additional 24,000 shares during the period. Bronfman E.L. Rothschild L.P. lifted its stake in shares of DENTSPLY SIRONA by 78.7% in the 2nd quarter. Bronfman E.L. Rothschild L.P. now owns 11,886 shares of the medical instruments supplier’s stock worth $771,000 after purchasing an additional 5,236 shares during the period. Gateway Investment Advisers LLC lifted its stake in shares of DENTSPLY SIRONA by 8.4% in the 2nd quarter. Gateway Investment Advisers LLC now owns 19,408 shares of the medical instruments supplier’s stock worth $1,258,000 after purchasing an additional 1,499 shares during the period. Finally, Delta Lloyd Asset Management N.V. bought a new position in shares of DENTSPLY SIRONA in the 2nd quarter worth approximately $15,624,000. Hedge funds and other institutional investors own 93.71% of the company’s stock.
About DENTSPLY SIRONA
DENTSPLY SIRONA Inc is a manufacturer of professional dental products and technologies. The Company develops, manufactures, and markets solutions offering, including dental and oral health products, as well as other consumable medical devices. It operates through two segments: Dental and Healthcare Consumables, and Technologies.
Receive News & Ratings for DENTSPLY SIRONA Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.